Search the Newsreel

Jasper Therapeutics beats earnings expectations but stock falls 4%

Rapid Critical Metals (ASX:RCM) Gains 10% as Prophet River Drilling Approval Adds Gallium-Germanium Upside

HC Wainwright Issues Pessimistic Forecast for TRAX Earnings

HC Wainwright Issues Pessimistic Forecast for IPSC Earnings

Scribe Therapeutics (SCTX) Stock Analysis Report | Financials & Insights

Do USPH’s Softer Earnings and New CFO Appointment Reveal a Turning Point in Its Strategy?

What's Going On With Medicenna Therapeutics Corp Stock Sunday?

Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History

Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics (GLUE) reported widening net losses for Q2 and the first half of 2026, marking a significant shift from prior-year profitability. This financial downturn, with a net loss of US$87.9 million for the six-month period, deepens the investment risk, highlighting the company's …

Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf Filing - Has The Bull Case Changed?

Dianthus Therapeutics (DNTH) Is Up 6.5% After Unveiling DNTH312 Amid Wider Q2 Losses

Johnson & Johnson Purchases New Stake in Rapport Therapeutics, Inc. $RAPP

State of Wyoming Purchases New Position in Kymera Therapeutics, Inc. $KYMR

The State of Wyoming acquired a new position of 11,780 shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) valued at approximately $1.35 million during the second quarter. This comes as Kymera reported stronger-than-expected quarterly results with a significant revenue increase, although insiders sold a substantial amount …

1,849,445 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by Johnson & Johnson

Ocular Therapeutix (OCUL) Is Up 9.2% After Wider Q2 Loss and New US$81.7M Shelf Registration

23,257 Shares in Corcept Therapeutics Incorporated $CORT Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP recently acquired a new position of 23,257 shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the second quarter, valued at approximately $2.022 million. Other institutional investors have also adjusted their holdings in CORT, with 93.61% of the stock owned by hedge …

Mineralys Therapeutics, Inc. $MLYS Shares Bought by Bank of America Corp DE

Wall Street Zen Upgrades Avalo Therapeutics (NASDAQ:AVTX) to Hold

Wall Street Zen has upgraded Avalo Therapeutics (NASDAQ:AVTX) from a "sell" to a "hold" rating, though the consensus among other analysts remains a "Moderate Buy" with an average price target of $45.10. The company reported a quarterly loss of $0.83 per share, missing estimates. …

Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen has upgraded Atara Biotherapeutics (NASDAQ:ATRA) from "Sell" to "Hold," reflecting an average "Hold" consensus among analysts with an average price target of $9.50. Despite the upgrade, ATRA shares opened down 4.9% at $8.09, with the company reporting a quarterly loss of …

Should I buy Scribe Therapeutics Inc. (SCTX)

Price-Driven Insight from (ZVRA) for Rule-Based Strategy

This article provides a price-driven analysis for Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, and an exceptional risk-reward short …

Arcutis (ARQT) Q2 2026 Earnings Call Transcript

Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress

Nektar Therapeutics' stock fell 4% following its Q2 2026 earnings report, despite progress in its autoimmune pipeline, notably rezpegaldesleukin. The market reacted negatively to the company's substantial cash burn, with a quarterly net loss exceeding US$40 million and trailing 12-month losses widening. While the …

How Rapport Therapeutics Inc. (RAPP) Affects Rotational Strategy Timing

This article analyzes Rapport Therapeutics Inc. (RAPP) using AI models to determine its effect on rotational strategy timing. Key findings suggest a strong sentiment supporting an overweight bias, with resistance being tested. The analysis provides specific institutional trading strategies, including position trading, momentum breakout, …

Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) reported a Q2 loss of $0.31 per share, which was better than the Zacks Consensus Estimate of a $0.42 loss. However, the company missed revenue estimates, posting $5.15 million against an expected $5.43 million. Despite beating EPS estimates two out …

How TG Therapeutics’ Q2 2026 Revenue Surge And Higher Guidance At TG Therapeutics (TGTX) Has Changed Its Investment Story

US Physical Therapy Appoints New Executive Vice President CFO

Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker

An insider at Zevra Therapeutics (ZVRA) has filed a Form 144 notice to resell up to 42,666 common shares. These shares are linked to restricted stock units granted in June 2025 and are planned for potential sale on NASDAQ. The filing also references previous …

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat

ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal

What date does Scribe Therapeutics Inc.'s (SCTX) report Earnings - Earnings Calendar & Announcement

TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC

This article provides current stock price information for First Tracks Biotherapeutics, Inc. (TRAX) on MEXC, detailing its live price, market data, and recent performance. It also includes instructions on how to buy TRAX on MEXC and offers a company overview, including its focus on …

Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026

Iovance Biotherapeutics, Inc. stock has rallied over 130% in 2026, closing at $6.98, but is showing strong overbought signals across multiple timeframes with daily RSI at 73.02. While the daily trend remains bullish due to strong EMA alignment and positive MACD, the elevated RSI …